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ABSTRACT 
 
 Hepatitis C virus affects 170 million people worldwide and until recently, 
therapeutic options have been limited. Novel and effective protease inhibitors (PI) 
became available in the clinic in 2011, and a plethora of new compounds and classes of 
compounds have been developed since. Due to the HCV polymerase lacking a 
proofreading mechanism, resistance to these compounds arises and decreases the success 
rate of treatment. Classically, drug resistance has been studied in the context of a system 
that does not recapitulate the entire HCV life cycle. With an established cell culture 
model of HCV infection in our lab we developed a novel assay for characterization of 
mutations conferring resistance to direct-acting antiviral compounds. We designed, 
improved and validated the assay with compounds stemming from different chemical 
classes including an NS3/4A inhibitor, NS5A inhibitors and NS5B inhibitors. Herein we 
present the development and implementation of the assay. With this assay in hand a more 
comprehensive understanding of HCV drug resistance can be realized and used as a tool 
for future drug development, both in HCV and in other related viruses.   
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Chapter 1 Introduction 
Overview 
 
Estimates of the global disease burden of hepatitis C virus (HCV) vary widely, but 
comprehensively approximate the global infection to be between 64 and 185 million 
individuals1–4. The prevalence of infection varies greatly by country worldwide. In Canada the 
infection rate is estimated to be 0.8%5, conversely in Egypt the prevalence is approximately 20% 
due to the negligence of sterility during parenteral antischistosomal therapy 6.  
A blood-borne virus, HCV is commonly spread through injection drug use and associated risk 
behaviours in the modern world7. Preceding the advent of serological and nucleic acid testing8 
the primary route of viral transmission was blood and blood product transfusions (as reviewed 
in 9). 
Acute infection with HCV is often asymptomatic and difficult to diagnose, leading to a large 
proportion of those infected to develop chronic infection10. Chronic HCV infection leads to the 
development of liver fibrosis, cirrhosis and an increased risk of hepatocellular carcinoma (HCC). 
With all of the preceding hepatic sequelae it is no surprise that chronic HCV infection is quickly 
becoming the leading cause of liver-related deaths worldwide11–13. 
In recent years there has been a rapid evolution of pharmaceutical interventions available to 
treat HCV-infected individuals (As reviewed in 14).  In the era of these new treatment options, 
clearance of the virus, also known as a sustained virological response (SVR), is becoming more 
and more common and leading to a wide range of health, social and economic benefits15. 
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Interestingly, companies have begun to subsidize HCV treatments in an effort to provide 
treatment globally16. However, the pressure of the HCV epidemic on the North American 
healthcare systems will not be relieved until the controversially expensive and seemingly 
monopolized treatment options become widely available and affordable, and active screening 
and social programs preventing novel infections are in place17,18 
Discovery of the Virus 
 
HCV was originally identified in 1975 as non-A non-B hepatitis (NANBH)19,20. Termed NANBH 
because some believed this form of hepatitis could be caused by more than a single infectious 
agent and should therefore not be referred to as the proposed “Type C”21,22 until the etiological 
agent(s) responsible for this form of hepatitis was explicitly identified20.  Soon after the 
speculation of a third form of hepatitis, the mode of transmission was investigated with both 
human samples and chimpanzee inoculations23,24; evidence suggested that the infection was 
likely passed from chronic carriers through blood sera.  
The infectious agent was suspected to be a virus and was titrated in chimpanzees, a high titer 
strain identified as Strain H became the staple for future analyses25. A major structural 
determinant of a virus is the presence or absence of a lipid envelope, to determine if an 
enveloped virus was responsible for NANBH, Strain H preparations were extracted with a 
common lipid solvent26. Using a convincing series of well-controlled experiments in 
chimpanzees, a NANBH infectious agent was shown to be sensitive to detergents and thus 
containing a lipid component necessary for transmission of infection26. To further characterize 
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the suspected virus, aliquots of Strain H were passed through filters ranging in pore size from 
100nm to 30nm27, the infectivity of the filtrates reflected a virus approximately 30-60nm in 
diameter.  
Despite valiant research efforts, the virus that caused NANBH remained a mystery until 1989 28. 
The discovery of the virus came in the form of an ingenious twist on a cloning protocol 
developed to isolate DNA encoding unknown proteins29. By modifying the protocol to identify 
clones created with antibodies from NANBH patients or chimpanzee sera it became possible to 
isolate and characterize the unknown viral genome. This seminal paper represented the 
identification of the virus as an enveloped, positive-stranded RNA virus which the authors 
speculated in the discussion belonged to the Flaviviridae family of viruses; HCV was explicitly 
identified.  
Natural History of Infection 
 
The progression of HCV infection is influenced by multiple host and viral factors and notably 
variable in the infected population (as reviewed in 30). Interestingly, only a small minority of 
those infected with HCV will present with symptoms during the acute stage of infection; 
decreasing rates of acute stage diagnosis 31,32. Of those infected approximately 15-25% will 
spontaneously clear the virus over a variable timeframe33–35, the remainder will progress to 
chronic infection leading to extrahepatic manifestations, fibrosis, cirrhosis and possibly HCC10–
13,36,37.  Figure 1.1 is a flow chart representing the natural history of infections. 
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Figure 1.1 Flow Chart of Viral Infection and Related Outcomes (modified from 36).  The asymptomatic 
nature of acute infection leads to a great number of infections being diagnosed during chronic stages, 
leading to high rates of liver disease.  
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Viral Genome  
 
HCV is a 9.6 kilobase positive-polarity RNA virus belonging to the family Flaviviridae28 and until 
recently was only accompanied by GB-virus B in the Hepacivirus genus (GB-virus B reviewed in 
38). The novel viruses in the genus have been termed nonprimate hepaciviruses, directly 
reflecting their eclectic infectious origins in rodents39,40, canines41,42, horses43, and bats44.   
HCV exists as seven primary genotypes (1-7) with each genotypic group containing several 
subtypes (a, b, c etc.)45–47.  Interestingly, although patients are diagnosed with a specific 
genotype, HCV circulates within each individual as a dynamic series of divergent sequences due 
to the error-prone nature of the viral polymerase48,49; this is referred to as a quasispecies. 
Considering the estimated viral production rate of 1012 virions per day50, and the estimated 
error rate of the polymerase, it has been mathematically determined that each mutation and 
combination of mutations can transiently exist in every patient every day51.  
HCV has a single open reading frame (ORF) between conserved 5’- and 3’-untranslated regions 
(UTRs) and initiates translation with an internal ribosomal entry site (IRES)52,53 located within 
the 5’ UTR to produce an approximately 3000 amino acid polypeptide. Interestingly, a liver 
specific microRNA, miR-122 has been shown to directly interact with the IRES and promote viral 
replication, further explaining the hepatotropic nature of HCV54. On the other end, the 3’ UTR 
contains a variable region, a polyU-polyUC tract and a highly structured terminal region 
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referred to as the 3’X tail. A pair of mutational studies highlighted the importance of each 
region and concluded that the 3’X tail was of the utmost importance for replication55,56.  
The polypeptide produced from the IRES-mediated translation of the HCV ORF follows a 
common Flaviviridae organizational pattern with structural proteins preceding non-structural28. 
The polypeptide is processed by viral and cellular proteases to produce 10 proteins, in order 
from 5’ to 3’, Core, Envelope 1 (E1), E2, p7, Non-structural 2 (NS2), NS3, NS4A, NS4B, NS5A and 
NS5B57.   Figure 1.2 depicts the viral genome organization. 
Viral Life Cycle 
Virion Structure, Receptor Binding, Entry and Fusion 
 
The HCV virion consists of a nucleocapsid comprised of oligomerized core protein and a single 
copy of the RNA genome, the nucleocapsid is surrounded by a lipid envelope, viral envelope 
proteins E1 and E2, and host Low-Density Lipoproteins (LDL), as represented in Figure 1.3 (as 
reviewed in 58 ).The inclusion of serum lipoproteins in the virion membrane leads to an 
unusually low buoyant density, and redefines the virion as a lipoviral particle (LVP)59–61. The 
presence of LDL as part of the virion is actually quite common in Flaviviruses, and promotes 
endocytosis through interaction with LDL receptors on target host cells62. Interestingly, imaging 
studies have revealed that the virion is pleiomorphic and does not closely resemble any other 
Flaviviridae virion structures63.  
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Figure 1.2 The Viral Genome, Polypeptide and Cleavage Sites (modified from64). HCV has a positive 
polarity RNA genome that is translated via an internal ribosomal entry site (IRES) in the 5’ non-coding 
region. The resultant polypeptide is then cleaved by host and viral proteases as indicated by the 
coloured arrows. Of note, core is also processed by signal peptide peptidase. Structural proteins core 
(C), envelope 1 (E1) and envelope 2 (E2) are indicated with white font and non-structural proteins are 
indicated in yellow. For the purposes of this figure p7 was included as a non-structural protein but has 
truly yet to be designated as structural or non-structural.  
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The first host receptor identified to be necessary for HCV infection was Cluster of Differention 
81 (CD81), a nearly ubiquitously expressed tetraspanin that was proposed to bind E2 at an 
initial entry step65.  Soon after, it was discovered that the LDLs present on the LVP play a major 
role in promoting HCV entry through the LDL receptor, and glycosaminoglycan receptors act at 
a recognition step preceding infection62,66.  Within a few years another candidate receptor was 
identified when E2 interactions leading to entry were shown to be cell specific. The human 
Scavenger Receptor Class B Type 1 (SR-BI) was suggested to act as a co-receptor bound by E267.  
A tight junction protein, claudin-1 (CLDN1) was shown to also play a key role in mediating the 
late steps of entry, and could be used to make non-hepatic cell lines susceptible to HCV 
infection68. Interestingly, within two years another tight junction protein, namely, occludin, was 
identified and reiterated the importance of HCV entering through the tight junction69. Finally, a 
cholesterol uptake receptor, Niemann-Pick C1-like 1 (NPC1L1), was identified and suggested as 
a convenient antiviral target  due to the availability of previously NPC1L1 targeted FDA-
approved compounds70.  All of these receptors play key roles in mitigating viral recognition and 
entry and the complete process is reviewed in 58 and represented in Figure 1.4.  
HCV enters the cell via clathrin-dependent endocytosis following the binding of host receptors 
and requires a low-pH step within the early endosome to mediate complete entry and fusion of 
the virion with the endosome71–74. The exact mechanism of fusion remains poorly understood 
but modern work suggests that several of the host receptors identified play key roles in the 
conformational changes of the envelope glycoproteins in the acidic endosomal compartment  
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Figure 1.3 Structure of the Hepatitis C Virion. The hepatitis C virion is comprised of a nucleocapsid 
consisting of core protein, not depicted in this figure, a host lipid membrane depicted in blue, E1 and E2 
heterodimers depicted in yellow and host lipoproteins depicted in red and orange.  The structure of the 
virion is pleomorphic and does not closely resemble any other member of the Flaviviridae family. 
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leading to fusion and release of the nucleoscapsid75. E2 was primarily suggested to be a class II 
fusion protein responsible for the release of the nucleocapsid and the viral genome76. 
Conversely, recent data on pestiviral entry has led to the development of hypotheses that E1 is 
actually functioning as a novel form of fusogen77,78. Figure 1.4 represents virion entry into 
hepatocytes via cellular receptors, endocytosis and fusion. 
Translation and Polyprotein Processing  
 
Translation of the RNA genome is initiated through the action of the IRES at the 5’ terminus52,53.  
Translation results in an approximately 3000 amino acid polyprotein that is co- and post-
translationally cleaved by host and viral proteases57,79. The structural region of the polyprotein 
is cleaved by host proteases80 notably associated with the endoplasmic reticulum (ER), the NS 
proteins are cleaved by the actions of NS2-NS3 to liberate themselves, and NS3/4A81 acting on 
the remainder of the polyprotein cleavage sites82. Figure 1.2 depicts the proteases responsible 
for cleavage and their proteolytic target sites.  
Replication  
 
HCV has a unique approach to replication when compared to other viruses within the Flavivirus 
genus83. Replication of HCV takes place in multiprotein complexes associated with a virally-
induced rearrangement of the ER termed the membranous web (MW)84. Interestingly, the 
multiprotein complexes responsible for replication are housed in double membrane vesicles 
(DMV), and it is hypothesized that eventually the stress of replication leads to the formation of 
multiple membrane vesicles85. By rearranging the host ER into a series of membranous  
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Figure 1.4 The HCV Life Cycle (modified from14). The viral life cycle, starting with free virus encountering 
a hepatocyte. 1) HCV interacts with the host hepatocyte via interactions between E1/E2 and CD81 and 
SR-BI 2)The virion is moved to the tight junction between hepatocytes, interacting further with tight 
junction proteins claudin and occludin 3) Following fusion the capsid is released, uncoated and free RNA 
is released 4) RNA is translated at the ER via IRES-mediated translation 5) The translated polypeptide is 
processed and mature proteins begin to form replication complexes within the virally-induced 
membranous web 6) Lipid droplets (purple) associated with the membranous web are used to load core 
and the viral genome to assemble viruses within the ER lumen, where they are eventually transported to 
the Golgi apparatus 7) Nascent particles are trafficked through the Golgi 8) Virus is exocytosed and 
released into the extracellular environment. Of note, HCV has been proposed to undergo direct cell-to-
cell transfer and be infectious as RNA transferred via exosomes.  
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replication complexes local concentrations of metabolites are increased, viral proteins and RNA 
are hidden from intracellular immune surveillance, and enzymatic interactions are tightly 
regulated (as reviewed in 86).   
The replication complex consists of NS3/4A, NS4B, NS5A and NS5B coordinated with host 
proteins in the DMVs (as reviewed in 87). It is the concerted action of these proteins that make 
both the replication complex and replication itself possible. Replication occurs in two steps, 
both mediated primarily by the RNA-dependent RNA polymerase (RdRp) NS5B88–91. The first 
step requires polymerization of a negative strand of RNA mediated by using the positive strand 
as a template; the second step produces viral genomes for packaging by using the nascent 
negative strand produced in the first step. There is an approximately one log-10 ratio of positive 
strand RNA being produced to negative strand (as reviewed in 92). The circulating viral 
heterogeneity originates with the propensity of NS5B to make errors during these replication 
steps48,49.  
Assembly and Egress 
 
Assembly of the HCV virion requires the consolidation of the structural proteins, a nascent RNA 
genome and several host proteins responsible for the low density of the LVP (as reviewed in 58). 
An important component of this process is the trafficking of the homodimerized core protein to 
cytosolic lipid droplets (cLDs), which are thought to act as a platform for nucleocapsid 
formation93,94. The nature of the core proteins’ RNA binding and lipophilic regions95,96 and the 
spatial organization of its localization on the membranes of cLDs prime assembly of a 
nucleocapsid harbouring a genome within premature viruses97. The envelope glycoproteins E1 
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and E2 are translated and remain associated with the budding endoplasmic reticular membrane 
as non-covalent heterodimers during this process98. Notably, this process is highly regulated by 
host and viral proteins and the concerted action of these factors leads to the transfer of core 
protein to the cLDs and eventually to the nascent virus budding in the ER99–102.  
In tandem with structural and host proteins, the non-structural proteins each have pivotal 
functions during assembly. NS2 and p7 both play critical roles in the viral assembly process (as 
reviewed in 64 ). NS2 has been reported to orchestrate the interaction of envelope proteins and 
the non-structural proteins involved in assembly, acting as a keystone during the initial steps of 
this process103–105.  The enigmatic p7 protein and its actions during the viral life cycle remain to 
be fully characterized, but mutational studies suggest a critical role along with NS2 during early 
morphogenesis106.  p7 has further been speculated to act as a viroporin107, preventing 
premature degradation of the envelope glycoproteins during morphogenesis108. 
 A great deal of genetic evidence has been gathered reflecting the importance of the helicase 
domain in NS3 and the NS4A cofactor in the process of assembly58. The NS3 helicase has been 
shown repeatedly to play a significant role in the process of assembly through mutation, 
deletion and adaptive studies109–111. NS4A has been linked to interactions with NS3 in assembly; 
an NS4A mutant that was shown to be assembly-defective can be rescued by an NS3 mutation 
outside of the protease domain, providing evidence that these non-structural proteins interact 
during the assembly process112. 
As mentioned previously, NS5A serves a plethora of purposes within the viral life cycle and 
interacts with numerous host and viral proteins58. A critical phosphorylation state in domain III 
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of NS5A has been hypothesized to bridge the gap between the replication complex and the 
initial stages of assembly113. Furthermore, it has been observed that domain III of NS5A has an 
intimate connection with the unloading of core protein from lipid droplets114, and this aligns 
well with data suggesting that the interaction between these two proteins correlates with the 
efficiency of virus production115.  Taken together, assembly is a complex and intricately 
organized process that remains to be fully elucidated.  
Host microRNAs and Viral Regulation  
 
As mentioned previously, miRNA-122 plays a significant role in the HCV life cycle, but beyond 
this direct interaction with the RNA genome host miRNAs perform a variety of functions in 
metabolic regulation and immunomodulation during infection (as reviewed in116 ). IFN-β has 
been previously shown to activate several miRNAs with anti-viral effects in the HCV life cycle117, 
and although several miRNAs were predicted to bind to HCV directly, host pathway modulation 
may also play a role during infection.  Recently, two miRNAs were implicated in the association 
of a single nucleotide polymorphism in the IFN-λ3 (IFNL3) gene with a decreased response to 
exogenous IFN therapy118.  The deleterious polymorphism conveyed an increased susceptibility 
of host mRNAs to AU-rich element-mediated decay and degradation by miRNAs induced by HCV 
infection.   
HCV induces modulation of cellular lipid metabolism to create an environment conducive to 
viral production14,116, one way in which the virus does this is through induction of miRNA 
pathways.  Changes to host lipid metabolism can often lead to a form of lipid accumulation 
termed steatosis119. HCV genotype 3 infections have a strong association with steatosis and 
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genotypic comparisons in vivo and in vitro provided the means to identify the downregulation 
of phosphatase and tensin homolog (PTEN) in a post-transcriptional manner120, mimicking a 
similar mechanism in non-alcoholic steatohepatitis. Furthermore, a comparative study 
analyzing miRNA expression in either genotype 3a or 1b core-expressing Huh-7 cells implicated 
several miRNAs involved in cellular metabolism and growth121. 
These are just a few examples of miRNA modulation in HCV infection. Recently, two more 
dysregulated miRNAs were shown to intimately link immunomodulation and lipid metabolism 
by collaborative work with colleagues at the University of Ottawa that was subsequently 
published in Nature Chemical Biology122. Recent work has identified an interferon-stimulated 
gene product 25-hydroxycholesterol (25-HC) as a mediator of antiviral activity in several 
viruses, including HCV123–125. This lipid effector has been linked to membrane modification 
inhibiting viral entry and intracellular metabolic pathway regulation.  Two intracellular 
metabolic pathways regulated by both 25-HC and HCV infection are the liver X receptor α 
signalling pathway126–128 and sterol element-binding protein processing125,129–131. Considering 
the role of 25-HC in membrane modifications, a control oxysterol that could not act on 
intracellular pathways was tested against HCV and had no antiviral effect, implicating metabolic 
regulation as the route of antiviral efficacy. miRNA profiling was performed and two miRNAs of 
interest were identified and characterized further. miRNA-130b and miRNA-185 both regulate 
hepatic lipid metabolism and are influenced by 25-HC and HCV infection. As part of our 
collaboration we analyzed the effects of knocking down these miRNAs during an in vitro viral 
infection (Appendix 1). The regulatory cycle identified with this work is outlined in Figure 1.6.  
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Model Systems 
 
The field of HCV research has experienced a dramatic evolution of laboratory techniques since 
the identification of NANBH. Over the years there have been several technical breakthroughs, 
but for the purposes of this thesis, I will focus on the four major developments that 
exponentially increased the potential for HCV research. As mentioned previously, when 
research began on NANBH, chimpanzee infection was the primary model of disease spread and 
virological characterization. This led to the initial characterization of the infectious agent, which 
undoubtedly supported the eventual discovery of HCV. The chimpanzee model of infection 
remains a physiologically relevant model for analysis of innate and adaptive immunology and 
pathogenesis (animal models reviewed in 132).  
Ten years after the discovery of the virus, a great leap forward came in the form of the replicon 
system133.  The authors of this seminal paper originally attempted to grow fully infectious virus 
with full length clones of a patient isolate. Following failure of this approach, they engineered 
bicistronic constructs with an antibiotic resistance gene to select for cells harbouring replicating 
virus. Similar bicistronic constructs had been previously established in flavi 134 and pestivirus 135 
systems. These constructs were commonly referred to as subgenomic replicons. These 
replicons only express the non-structural proteins and represented a major breakthrough for 
the study of replication and the development of antiviral compounds.  
One of the major limitations of the replicon system is the absence of structural proteins and the 
inability of the replicon to generate virus particles. To address this, in 2003, Bartosch et. al. 
17 
 
established what was termed a pseudoparticle system136 and within months Hsu et. al. 
published a similar system137. These systems revolved around expressing the viral packaging 
machinery of HIV and the HCV envelope proteins to create chimeric pseudoparticles. Using 
either GFP136 or luciferase137 markers of infection, these systems provided the means to 
characterize the HCV envelope proteins and the process of viral entry.  
What both of these previous systems failed to recapitulate was the entire viral life cycle of HCV.  
In 2005 a system was discovered based on a patient sequence that required no adaptation to 
grow in cell culture, the sequence came from a Japanese patient with fulminant hepatitis and 
was aptly abbreviated JFH1138,139. Quickly following this discovery chimeric viruses were 
designed and the doors swung open to widely applicable mutagenesis studies 140.  
The original viral strain replicated in cell culture albeit at low levels, but with its discovery came 
the possibility of viral adaptation to cell culture conditions. One adaptive strain of particular 
interest for the work to be presented herein is the JFH1T virus108,110,141. JFH1T contains three 
adaptive mutations, one each in E2, NS2 and p7, these mutations increase the production of 
virus and make it possible to analyze highly relevant mutations that would otherwise be lethal 
in culture. All of the experimental work for this thesis was done with this adapted viral strain.  
Finally, the development of a convenient and relevant mouse model has eluded the scientific 
community for decades. A complicated transplant mouse model142 served as the only small 
animal system until very recently when transient143 and eventually stable expression144 of viral 
entry receptors in mice facilitated viral replication. This novel approach developed by Ploss 
et.al. may serve to be the breakthrough necessary to facilitate in vivo analyses of viral infection 
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and pathogenesis, but the model has a low production of virus and the efficacy of the system in 
multiple studies is yet to be determined.   
Treatment and the Evolution of Standard of Care 
 
Recently, there has been a massive expansion of available compounds for the treatment of 
HCV, but the history of HCV care precedes its discovery (evolution of care reviewed in 14). The 
treatment of HCV has evolved from the use of modified cytokines and broad spectrum antivirals 
to the use of specifically-acting compounds targeting both host and viral factors during 
infection. This dramatic transformation of therapeutic options has been the result of the 
evolution of scientific tools and industrial approaches to drug development. Despite all of the 
progress to date on treatment issues such as resistance, patient comorbidities and 
pharmaceutical financial discrepancies still hinder the real world efficacy of these 
compounds145,146. 
Interferon and Ribavirin 
 
As early as 1986 recombinant alpha interferon was being investigated to control the hepatic 
alterations caused by NANBH. Primary outcomes were assessed based on liver enzyme tests 
and histological analysis147. By 1990 several randomized controlled trials had been performed 
with interferon alpha and immediate positive outcomes in a minority of patients had become 
apparent148.  In 1998 an addition to interferon monotherapy came in the form of Ribavirin149 
and approximately doubled the response rate to treatment but came with additional side 
effects. The final breakthrough impacting the classical standard of care came in 2001 with the 
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approval of polyethylene glycol-conjugated interferon alpha (PEG-IFN). By addition of these 
chemical groups the half-life of the protein in vivo was increased drastically and PEG-IFN 
became the recommendation of choice for treatment in combination with ribavirin150–154.  In 
2009 a major clinical advance came in the identification of the correlation between host IL28B 
alleles and success of treatment with PEG-IFN155,156. This observation led to the optimization of 
standard treatment algorithms preceding the approval of any specific antiviral compounds (as 
reviewed in 157). 
Host-Targeting Antivirals 
 
The first host-targeting antivirals to move into clinical development were cyclosporine A and 
analogues of cyclosporine A, all of which suppress the activity of cyclophilin A158. The most 
promising of this group of compounds was termed alisporivir159,160. Cyclophilin A is a host 
enzyme with isomerase activity that has been shown to interact with NS5A to promote 
replication161. Work with these inhibitors and cell culture systems reiterated the importance of 
this interaction and demonstrated that resistance mutations reduced the dependence of the 
viral replication cycle on the enzymatic actions of cyclophilin A162. Although these compounds 
have shown great promise in clinical trials alone, the most advanced of the compounds in 
combination with the classical standard of care has led to the development of pancreatitis in 
isolated cases and is now on clinical hold163. Considering the severity of some adverse events it 
has been suggested that these compounds are better suited for interferon-free combination 
therapy (reviewed in 14).  
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In 2008, a modified oligonucleotide termed SPC3649 was identified as the result of a large 
screen of similar compounds designed to inhibit miR-122164. This compound was shown to 
reduce cholesterol levels in vivo and similarly inhibit HCV infection in vitro. As mentioned 
previously, miR-122 plays a significant role in viral replication and has been implicated in 
protecting the viral genome from host nuclease digestion as well as enhancing viral 
translation54,165,166. The discovery of this inhibitor, now termed miravirsen, represents a 
significant leap forward in therapeutics as miravirsen has the potential to be the first approved 
therapy of its kind (as reviewed in 167). Miravirsen is currently in Phase 2 trials and seems to be 
a promising candidate for future treatment regimens.  
Both miravirsen and alisporivir have no genotype-specific targets and thus provide pan-
genotypic additions to approved therapeutic regimens. Considering the these compounds 
target host proteins, it comes as no surprise that there has been no viral resistance observed to 
date in vivo. The host-acting antivirals described here will no doubt play a role in interferon-free 
therapy and significantly impact pan-genotypic treatment options (as reviewed in 14). 
 
Direct-Acting Antivirals 
 
A plethora of direct-acting antivirals (DAA) targeting multiple points during the hepatitis C viral 
replication cycle have become available over the last 4 years14. Protease Inhibitor (PI) 
development showed the first signs of success in 2003 with the compound BILN-2061, a 
revolutionary protease inhibitor that opened the door to subsequent successful therapies168. 
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The first approved PIs came in 2011 with telaprevir and boceprevir in 2011, both NS3/4A PIs 
were the pioneering compounds in the DAA field and were quickly integrated into standard of 
care for genotype-1 patients along with PEG-IFN and ribavirin169–171.. Both boceprevir and 
telaprevir are linear peptidomimetic compounds that act on the proteolytic active site of NS3. 
These compounds stemmed from a rational design approach to mimic the natural substrate of 
the viral protease (as reviewed in 172). Additionally, a second wave of protease inhibitors with 
similar designs to the first wave and a second generation of optimized compounds are in clinical 
development (as reviewed in 173). As recently as 2013 a macrocyclic protease inhibitor termed 
Simeprevir has been FDA-approved for combination therapy with PEG-IFN and ribavirin174,175. 
Protease inhibitors have a low barrier to resistance, meaning that mutations conferring 
resistance to this class of inhibitors arise early and can be sustained in the viral 
quasispecies176,177. Several variably fit mutations repeatedly arose during clinical trials172. The 
fitness of a mutant is defined as the replicative capacity, and often in terms of HCV is defined as 
the ability of mutant viruses to replicate in the presence of wild-type virus, reflective of the 
effects of mutations in a quasispecies172, that is to say a highly fit virus has a high replication 
capacity and can be maintained in a quasispecies. The approval of these compounds symbolize 
a major breakthrough in viral therapeutics as they are the first specifically designed inhibitors 
with the ability to cure a chronic infection and have significantly improved SVR rates in 
genotype-1 infected populations14.  
Another major pharmaceutical advance came in the form of Sofosbuvir in 2010178 and it’s FDA 
approval in 2013179. A markedly different inhibitor, this compound acts as a nucleotide 
analogue, inhibiting polymerization after incorporation into a nascent viral RNA strand. This was 
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the first inhibitor to be paired with Ribavirin in an interferon-free regimen and illustrated the 
plausibility of an interferon-free therapeutic landscape180. Sofosbuvir significantly improves SVR 
rates in triple therapy, and due to the compound’s mechanism of action has a pan-enotypic 
potential181. A single resistance mutation has been observed with Sofosbuvir treatment, S282T. 
S282T rarely arose in clinical trials182 but patients being excluded from clinical trials may 
represent a more complicated population to treat183. Several allosteric NS5B inhibitors are in 
development but none have met FDA approval and this class is riddled with highly genotype-
specific compounds that are speculated to only be useful in DAA combination therapies 
(Detailed review of all NS5B compounds184)  
Over the last year, a potent class of NS5A inhibitors, including Daclatasvir and Ledipasvir, has 
become a prioritized focus for companies interested in developing combination therapies185–191. 
The mechanism of action of this class of inhibitor remains ambiguous, but resistance data maps 
the interactions to domain I of NS5A at the homodimer interface190 and data suggests that 
these compounds inhibit both replication and assembly in temporally distinct manners192. 
These discoveries and approvals serve as examples of the dramatic therapeutic reform taking 
place in the field of hepatitis C.  
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Project Design and Hypotheses 
 
The field of HCV antiviral resistance mapping, phenotyping and compound discovery has 
primarily been advanced with the replicon system14. Analysis of compounds in replicons 
provides early data and plausible resistance mapping, that is to say that genomic positions 
containing resistance mutations offer insight into any given compounds mechanism of action. 
Although it is an excellent tool, mutations arising in the replicon system could be due to a lack 
of genetic pressure on portions of the genome essential for assembly, and thus represent 
artifacts rather than bona fide resistance mutations. Considering the size of the HCV genome, it 
comes as no surprise that the virus has evolved with polyfunctional non-structural proteins. 
Thus the HCV life cycle is inherently complex and regulated by a labyrinth of interactions 
amongst both viral and host proteins. To fully comprehend the efficacy of antiviral compounds 
and/or the prominence of resistance in vitro, a fully infectious system needs to be implemented 
when dealing with compounds inhibiting proteins acting at points outside of the replication 
cycle. Several groups have used cell culture systems to analyze resistance192–195, but these 
assays have yet to be fully embraced and implemented due to technical or theoretical caveats. 
With this in mind we set out to develop an assay in a fully infectious viral system that was easy 
to use and best recapitulated the in vivo setting.  
To begin we searched the literature for PI-resistant mutations that were prominently 
represented in vivo and in vitro. We further specified our selection criteria by choosing 
telaprevir and boceprevir cross-resistant mutations that spanned the entire 180 a.a. protease 
domain of NS3. To increase the potential for future analyses, we selected mutations that arose 
24 
 
together or individually in the literature. This led us to select four mutations to introduce into 
our adapted virus. The virus used for all of this work is a genotype-2a construct with three 
adaptive mutations, one each in E2, p7 and NS2108,110,141. Notably, there is no adaptive mutation 
in the NS3 protein to be manipulated. We hypothesized that these mutations would reduce the 
fitness of the virus as measured by a focus forming unit (ffu) assay and exhibit a PI-resistant 
phenotype. We confirmed our results with one mutation in a competition assay and assessed 
the potential for select mutants to revert to wild-type in a long-term passage. We were also 
interested in the correlation between fitness and the frequency of the mutations observed in 
the literature, presumably the more often the mutation is observed the more fit it would be in 
our system. That being said, the fitness is a reflection of a much greater number of factors in 
vivo than in vitro, and the majority of sequences identified in the clinic stemmed from HCV 
genotype-1 infected patients.  
Following our initial analyses of potential drug resistant mutant fitness, we went on to develop 
and optimize an assay for evaluating compound efficacy. We hypothesized that compounds 
tested would inhibit wild-type virus at concentrations similar to those reported in the literature. 
The objective of this development was to provide a tool to the scientific community for 
evaluation of novel compounds in the context of a complete viral replication cycle. As 
secondary objectives, we designed the assay to be increased in throughput, and to be easily 
replicated in other labs. With this in mind, we began with 6-well plates, we used commercially 
available quantitative reverse-transcription polymerase chain reaction (QRT-PCR) reagents and 
harnessed the high dynamic range of the JFH1T virus mentioned previously (Up to 106 ffu/ml). 
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Project Aims 
 
i. Assess the fitness of common protease inhibitor resistance mutations in the context of JFH1T, 
and confirm any correlation between mutation frequency in patients and fitness in our 
construct. 
ii. Develop and optimize an assay to phenotype resistance mutations in the context of a 
complete life cycle and confirm their potential resistance in a genotype-2a construct. 
iii. Test novel compounds as a proof-of-principle that the assay is functional with multiple drug 
classes.  
Chapter 2 Materials and Methods 
 
Plasmids and cloning  
JFH1T contains three amino acid substitutions encoded by one mutation each. There is one 
mutation each in E2, p7 and NS2. The JFH1T construct is derived from a cell culture-adapted 
version of JFH1, with mutations leading to greater infectious virus production141. Mutations in 
the protease: L36M, T54A, R155K, and I170A were all introduced using the Quikchange II XL 
site-directed mutagenesis kit (Agilent Technologies). Forward primers were as follows from 5’ 
to 3’: L36M: GGGGAAGTCCAAATCATGTCCACAGTCTCTCAG, T54A:  
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GGGGTTTTGTGGGCAGTTTACCACGGAGCTGGC, R155K: 
GTCGTTGGGCTCTTCAAGGCAGCTGTGTGC, I170A: GCCAAATCCATCGATTTCGCCCCCGTTGAG 
ACACTCGAC. All reverse primers were complementary to forward primers listed. Primers were 
ordered as standard oligos (Life Technologies).  
Cell Culture 
Human Hepatoma Huh-7.5 cells were propagated in Dulbeccos Modified Eagles Medium 
supplemented with High Glucose, L-glutamine, phenol red and sodium pyruvate (DMEM; Gibco) 
supplemented with 10% Fetal Bovine Serum (FBS) (Gibco) and 1% Penicillin/Streptomycin 
(Sigma) to make complete DMEM (DMEM(comp)).  Cells were maintained at 37ᵒC and 5% CO2.  
Antibodies 
The following antibodies were used in this study: Primary Mouse anti-HCV core monoclonal B2 
antibody (Anogen), and secondary Alexafluor 488 goat anti-mouse (Life Technologies).  The 
core antibody was diluted 1:200 in 5% BSA in PBS and the Alexafluor 488 was diluted 1:500 in 
PBS.  
In vitro transcription and RNA transfection   
Plasmid DNA coding for JFH1T or the protease mutants of JFH1T was linearized by digestion with 
XBaI for 2 hours at 37ᵒ C. Linearized DNA was extracted from the digestion solution with 
UltraPure Phenol:Chloroform:Isomyl alcohol (Invitrogen) followed by ethanol precipitation. 
Linearized DNA was either stored at -20ᵒC or used directly for transcription. Twenty-four hours 
preceding transfection Huh-7.5 cells were seeded in 10cm dishes at a density of 1-1.5 x 106 cells 
per dish. On the day of transfection 1 µg of linearized DNA was transcribed using the T7 
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RiboMAX Express large-scale RNA production system (Promega). Plate medium was removed 
and replaced with 2 ml of serum-free (SF) medium/plate.  500 µl of SF medium, 50 µl of DMRIE-
C transfection reagent (Invitrogen) and 4 µl of RNA transcripts were mixed lightly. Transfection 
mixtures were then added to cells and incubated at 37ᵒC and 5% CO2 for 4 hours. Following 
incubation, SF medium was removed and replaced with 7 ml of DMEM(comp) . Transfected cells 
were incubated for 72 hours before supernatants were collected and clarified. 
For QRT-PCR standards, linearized DNA was transcribed as described above. The resulting 
solution was subjected to RQ1 DNase digestion (Promega) and RNA was extracted using Trizol 
LS (Invitrogen). The resulting RNA concentration was determined by spectrophotometer 
readings on a Biophotometer Plus (Eppendorf).  HCV genome copies in the resulting 
concentration were determined by using the molar mass of a genome. Once the genome copy 
was determined the solution was 10-fold serially diluted on ice until the concentrations of 108, 
107, 106, 105, 104, 103, and 102 per 2 µl were achieved. These standards were frozen at -80ᵒC 
until needed.  
Infectious HCV titer determination 
 Twenty-four hours preceding infection 8-well chamber slides (LabTek) were seeded with 5 x 
104 cells in 400 µl per well and incubated at 37ᵒC and 5% CO2.  72 hours post-transfection 
transfection media were collected and clarified by centrifugation at 1800 x g for 3 minutes. The 
clarified supernatants were aliquoted and frozen at -80ᵒC before use. Supernatants containing 
virus were then thawed and serially diluted 10-fold in triplicate in DMEM(comp). 100 µl from each 
dilution were used to infect each well of the 8-well chamber slides. Infections were incubated, 
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rocking every hour, at 37ᵒC and 5% CO2 for four hours. Following incubation inocula were  
removed and replaced with 400 µl of DMEM(comp) . 72 hours post-infection cells were fixed with 
acetone and stained with mouse anti-core and goat anti-mouse Alexafluor 488. Viral titers are 
expressed as focus forming units per millilitre (ffu/ml). 
Infection of 6-well plates: For the EC50 assay, 24 hours preceding infection, 6-well plates 
(Corning) were seeded with 1.5 x 105 cells per well. Cells were infected at an MOI of 0.1 
(defined as 15000 FFU) in 1 ml of DMEM(comp) and incubated for four hours before infectious 
media was removed and replaced with 3 ml of DMEM(comp) containing serial dilutions of the 
approved drug or the unapproved test compound of interest, the highest concentration of 
DMSO remained below 0.1%.. 72 hours post-infection medium was removed and clarified by 
centrifugation. Clarified supernatants were then stored at -80ᵒC preceding use.  
 
RNA extraction, QRT-PCR and EC50 determination  
Following clarification of supernatants RNA extraction was performed using the QIAamp Viral 
RNA Mini kit (Qiagen) and extracts were stored at -80ᵒC preceding use. QRT-PCR was 
performed on a 7500 Fast Real-Time PCR (Applied BioSystems) with a 5’ UTR primer and probe 
(ABI cat#: 4331182) and the Taqman Fast Virus 1-Step Master Mix. Standards and samples were 
run in triplicate. The primers and probe were previously designed by colleagues within the lab, 
namely Dr. Ali Atoom and Dr. Rodney Russell. Once designed the primers and probe designs 
became publically available through ABI. Genome copies/ml were used to plot the EC50 graphs 
in GraphPad Prism 5 (GraphPad) using a three-parameter dose response curve. Zero percent 
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inhibition was defined as the highest genome copy value in the data set; all other data points 
were transformed into a percentage of this value.  
Chapter 3 Fitness Analysis of Common Protease-Inhibitor Resistant 
Viruses 
Viral Production and Spread   
 
We selected four common PI resistant mutations to analyze in the context of our robustly 
replicating viral construct. The four selected mutations were: L36M, T54A, R155K and I170A. 
The rationale for the selection of these mutants is outlined in detail in the project design 
section of this thesis. We introduced these four mutations into the viral genome encoding 
portion of the plasmid independently to create four separate constructs via site-directed 
mutagenesis with custom primers. All mutated plasmid constructs were validated by Sanger 
sequencing at The Center for Applied Genomics in Toronto, Ontario, Canada.We transfected 
RNA stemming from mutated plasmids into Huh-7.5 cells to produce viral stocks. These stocks 
were then used to infect cells in 8-well chamber slides which were subsequently used for 
immunofluorescent analysis of the presence of viral core protein. Using this assay we can 
quantify virus production and qualitatively assess viral spread. To quantify, we followed a 
limiting dilution viral titer assay. Qualitative assessment of the size of each viral foci gave us 
indication of viral spread from cell to cell. Detailed description of these quantitative and 
qualitative viral techniques can be found in a seminal HCV paper published from Dr. Francis 
Chisari’s lab in 2005138 The least conservative mutant in terms of amino acid substitution, 
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I170A, showed the greatest reduction in virus production.  Aside from I170A minimal reductions 
in virus production were observed. The replication negative control, ΔGDD, which contains a 
three amino acid deletion within the active site of the viral polymerase, had no observable foci 
(Figure 3.1). Virus spread was similar amongst mutants and wild-type (Figure 3.2). Taken 
together these data indicate that the resistant mutations in our panel stemming from 
conservative amino acid changes produced virus within approximately one log of the wild-type 
construct and spread was minimally effected in each conservative construct.  
Confirmation of R155K Fitness Deficit and Analysis of the Potential for 
Reversion in T54A and R155K  
 
To confirm mutant viral fitness was indeed compromised we selected the mutations with the 
highest clinical frequency to analyze in a competition assay. This assay consisted of co-culturing 
the mutant with the wild-type virus at increasing ratios of mutant:wild-type. RNA was then 
extracted from co-culture supernatant and subjected to cDNA synthesis. Following cDNA 
synthesis, a PCR protocol was implemented to amplify the protease region of interest. PCR 
products were subjected to population sequencing and the codon of interest was identified as 
either mutant or wild-type for each ratio. We observed that at any ratio cultured except for 1:1 
the R155K codon remained dominant when competing with wild-type virus (Table 3.1). This 
confirmed the results of our previous experiment in which R155K was indeed less fit than wild-
type.  
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Figure 3.1 The Effect of Protease Inhibitor Resistant Mutations on Viral Production. Mutated viral 
plasmids were transcribed and RNA was subsequently transfected into Huh-7.5 cells at a density of 1 x 
106 per 10 cm plate. Supernatants were harvested 72 hours post-transfection and serially diluted before 
infecting Huh-7.5 cells at a density of 50 000 cells per well in 8-well chamber slides. 8-well chamber 
infections were incubated for 72 hours before media was removed, cells were fixed with acetone and 
stained for core protein. Foci were counted in the highest positive well of each dilution series and focus 
forming units (ffu)/ml was calculated accordingly. All mutants were tested in triplicate wells and the 
experiment was repeated three times. The ΔGDD construct is a replication negative control and the 
lower limit of detection is 10 ffu/ml141. Bars represent the mean of triplicate values.  
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Figure 3.2 The Effect of Protease Inhibitor Resistant Mutations on Viral Spread. Mutated viral plasmids 
were transcribed and RNA was subsequently transfected into Huh-7.5 cells at a density of 1 x 106 cells 
per 10cm plate. Supernatants were harvested 72 hours post transfection and serially diluted before 
infecting Huh-7.5 cells at a density of 50 000 cells per well in 8-well chamber slides. 8-well chamber 
infections were incubated for 72 hours before media was removed; cells were fixed with acetone and 
stained for core. Nuclei were visualized by staining with DAPI. Shown here are representative fields of 
view from representative mutants viewed with a 20X objective lens. No observable difference in viral 
spread was noticed in any construct. 
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Following up on work done by a previous lab member, the two most common mutations, T54A 
and R155K, were subjected to long-term passage in order to analyze the preferential genetic 
pathways to amino acid substitutions. This assay was designed to quantify the contribution of 
mutational bias to genetic barrier and test the hypothesis that mutations arise through 
energetically favourable means. Genetic barrier is defined as the number of mutations 
necessary to overcome selective drug pressure, the nature of the mutations (i.e. transition or 
transversion) and their combined impact on viral fitness172.  Mutational bias refers to the strong 
preference the polymerase displays for transitions (e.g. guanine to adenine) rather than 
transversions (e.g. guanine to cytosine or uracil) when making errors196. By passaging the 
mutant viruses for 15 days or more they are given ample opportunity to generate mutations 
that encode f the wild-type NS3 protein. If a wild-type protein coding sequence arises in culture 
it will out-compete the mutant virus and become the dominant sequence in the quasispecies. 
To assess the reversion characteristics of the T54A and R155K mutants they were cultured 
between 15-45 days and, similar to the competition assay, RNA was reverse transcribed, 
amplified and sequenced. In both mutant viruses no reversion was observed, this further 
emphasizes the fitness of the mutants in our system. Considering the negative nature of this 
result, no table is provided. 
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Table 3.1 Competitive Fitness of R155K. 10cm culture plates were seeded with Huh-7.5 cells at a density 
of 1 x 106 cells/plate and incubated for 24 hours preceding infections. Mutant and wild-type virus stocks 
were used to infect Huh-7.5 cells at increasing ratios of mutant to wild-type. A total multiplicity of 
infection (MOI) of 0.1 was implemented for every ratio and a plate with mutant virus containing no wild-
type was used as a control. Infections were incubated for 72 hours before supernatant was removed, 
RNA extracted, cDNA synthesized and PCR amplified for sequencing.  
 
Ratio Codon  Dominant Virus 
1 to 1 CGA  Wild-type 
10 to 1 AAG Mutant (R155K) 
100 to 1 AAG Mutant (R155K) 
Control AAG Mutant (R155K) 
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Chapter 4 Development of a Robust Virus-based Assay for Determination 
of Antiviral 50% Effective Concentration  
Note: The results in this chapter are currently being compiled into a manuscript that will be 
submitted to the journal Antimicrobial Agents and Chemotherapy. 
Confirmation of Resistant Phenotype in Common PI-resistant Mutants 
The conventional means to determine an EC50 in the HCV field is through the use of high 
throughput replicon systems14,172. The replicon system does not recapitulate the entire life 
cycle of HCV and so we sought to improve the accuracy of compound analysis by using the 
entire HCV life cycle. To establish our assay we began with the two most common protease 
inhbitor resistant mutations and a wild-type control. To measure the quantity of virus released 
into the supernatant we implemented a commercially available QRT-PCR protocol. We used a 
custom calculation of viral genomes and we tested the probe and the design of our standard 
RNA concentrations by a simple comparison of infected and uninfected wells (Figure. 4.1). We 
assessed the growth rates of the mutants and the wild-type virus in 6-well plates over 4 day 
cultures to assess whether growth would peak on day 3 or 4, commonly transfections or 
infections are incubated for 3 days in our lab for optimal yields, but because we were working 
with a new quantitation method, we expanded our curves to incorporate a 4-day incubation 
(Figure 4.2).  We set up a protocol using an MOI of 0.1 for 4 day culture based on the results of 
our growth curve. Although the growth curve gave us  insight concerning the optimum day to 
harvest we could not help but notice the high background levels observed with the replication 
negative control. With no increase in copy number in the control we believed the curves were   
36 
 
  
Figure 4.1 Initial Test of QPCR Assay with Primers and Probe. Huh-7.5 cells were seeded at 1.5 x 105 
cells/well in 6-well dishes. Cells were infected at an MOI of 0.1 or uninfected and incubated for 3 days. 
All samples were subjected to RNA extraction and QRT-PCR quantification on the same day following 
completion of the experiment.  Samples were quantified in duplicate and black bars represent standard 
deviation. 
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Figure 4.2 Analysis of Peak Viral Growth in 6-Well Cultures. Huh-7.5 cells were seeded at 1.5 x 105 
cells/well in 6-well dishes. Cells were infected at an MOI of 0.1 and incubated for 4 days. Supernatant 
was sampled every 24 hours, clarified and frozen at -80ᵒ C. All samples were subjected to RNA extraction 
and QRT-PCR quantification on the same day following completion of the experiment. Δ GDD served as a 
replication negative control. All samples were quantified in duplicate and bars represent standard 
deviation.  
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accurately representing growth qualitatively but may be overrepresented quantitatively. Our 
initial standard design was based on an in vitro transcription followed by concentration analysis 
by a spectrophotometer and then genome calculation based on the molecular weight of one 
HCV genome. To further increase the accuracy of our quantitation and better design our 
standards we followed the in vitro transcription step with DNA digestion with RQ DNase and 
then RNA extraction with the TRIzol reagent. We then followed the remainder of the protocol 
as specified previously and saw a dramatic decrease in total copy number leading us to believe 
that the previous standards were misrepresenting the data due to the presence of input 
template DNA, this reduction in copy number can be observed in Figure 4.3. Before testing any 
compounds we implemented a serial dilution of DMSO on the 6-well growth assay to assess the 
impact of the solvent and to identify a concentration that will have little to no effect on the 
yield of virus (Figure 4.3). Of note, in the 10% DMSO condition, cells showed a noticeably 
diminished ability to grow when observed under the light microscope, all other conditions 
phenotypically resembled no DMSO when observed similarly. The 10% DMSO was also the only 
condition to significantly vary from the no DMSO control condition when analyzed by QRT-PCR 
(Figure 4.3). Following this assay all compounds were resuspended to be implemented at a 
concentration of no more than 0.1% DMSO in complete media to minimize any impact of DMSO 
on virus replication and/or cell viability.  To calculate the EC50 of telaprevir in the context of 
JFH1T we tested the production of the virus in serial dilutions of telaprevir. Our data analyses 
led us to compare two types of constraints on the calculation of effective concentration. Upon 
constraining the maximum and minimum asymptotes to 100% and 0% respectively we saw a  
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Figure 4.3 Optimization of DMSO concentration in Huh-7.5 cells . Huh-7.5 cells were seeded at 1.5 x 105 
cells/well in 6-well dishes. Cells were infected at an MOI of 0.1 and incubated for 4 days with no DMSO 
or a serial dilution represented as a percentage of DMEM(comp).  Samples were quantified in duplicate 
and black bars represent standard deviation. 
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Figure 4.4 Comparison of Constrained and Non-Constrained Calculations. Representative EC50 graphs 
and corresponding effective concentrations. Huh-7.5 cells were seeded at 1.5 x 105 cells/well in 6-well 
dishes. Cells were infected at an MOI of 0.1 and treated with 10-fold logarithmic dilutions of telaprevir. 
The treated infections were incubated for 4 days. On day 4 supernatant was clarified and subjected to 
RNA extraction and QRT-PCR. EC50 analyses were carried out with Graphpad Prism software. All points 
were quantified in duplicate. Constrained calculations were performed by restricting the maximum and 
minimum asymptotes to 100% and 0% respectively. Non-constrained had no such restrictions. Numbers 
below graphs represent EC50 values expressed in Moles/L. 
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slight shift in effective concentration as visualized in Figure 4.4. The data curves were better fit, 
and therefore the data and effective concentrations were better represented when these 
constraints were relieved and therefore all subsequent calculations were performed without 
constraints. Finally, to confirm that the mutations chosen were indeed bona fide resistance 
mutations in our system we tested their replication capacity in the presence of increasing 
concentrations of telaprevir, one of the two clinically approved inhibitors of NS3171. Both T54A 
and R155K showed an approximately one log increase in the concentration necessary to inhibit 
viral growth by 50% (EC50), when compared to wild-type (Figure 4.5). This result confirms the 
resistant phenotype of the selected mutants in our system and serves as a proof of principle 
that our assay is functional for resistance analysis. 
Analysis of Novel Anti-HCV compounds 
 
Once the assay had been established with telaprevir and common resistant mutations, we 
received novel compounds developed by Dr. Raymond Schinazi’s laboratory at Emory 
University. These five compounds represented two additional distinct antiviral classes. RSRR-1 
and RSRR-2 are nucleoside analogues that were selected due to their interesting metabolic 
characteristics. RSRR-3, RSRR-4 and RSRR-5 represent NS5A targeting compounds and were 
selected for their antiviral potency and novel designs. Unfortunately, we are not permitted to 
share the chemical structure or specifics of each compound, but for the purposes of our work, 
knowledge of the chemical class suffices. We initially tested RSRR-1, 3, 4 and 5 at the suggestion 
of our collaborator (Figure 4.6). We observed EC50 values in the nanomolar range with the NS5B 
targeting compounds and EC50 values in the picomolar range with the NS5A targeting 
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Figure 4.5 Demonstration of Telaprevir-Resistant Phenotype. Representative EC50 graphs and 
corresponding effective concentrations. Huh-7.5 cells were seeded at 1.5 x 105 cells/well in 6-well 
dishes. Cells were infected at an MOI of 0.1 and treated with 10-fold logarithmic dilutions of telaprevir. 
The treated infections were incubated for 4 days. On day 4 supernatant was clarified and subjected to 
RNA extraction and QRT-PCR. EC50 analyses were carried out with Graphpad Prism software. All points 
were quantified in triplicate.  
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Figure 4.6 Demonstration of Assay Utility in Novel Compounds. Representative EC50 graphs and 
corresponding effective concentrations. Huh-7.5 cells were seeded at 1.5 x 105 cells/well in 6-well 
dishes. Cells were infected at an MOI of 0.1 and treated with 10-fold logarithmic dilutions of each 
compound. The treated infections were incubated for 4 days. On day 4 supernatant was clarified and 
subjected to RNA extraction and QRT-PCR. EC50 analyses were carried out with Graphpad Prism 
software. All points were quantified in triplicate.  
  
44 
 
compounds. This further confirmed the efficacy of our system as these ranges were commonly observed 
in the literature for these respective classes of compounds14 
Improvement of the EC50 Assay with a Novel Compound 
 
To increase the accuracy and validity of our assay we increased the number of dilutions used to 
test each compound. This strategy increased the total number of data points per graph and 
provided a better potential for curve-fitting. We decided to test the final compound of the five 
provided by Dr. Schinazi’s group in this fashion. RSRR-2 was 10-fold diluted 12 times and tested 
in the same fashion as the previous compounds (Figure 4.7. To further increase the accuracy of 
our curve, we analyzed the data points with both the standard fixed slope three-parameter 
(shown in red) and the variable slope four-parameter (shown in blue). The fixed slope 
parameters set the slope of the curve automatically to 1 or -1 and fits the data accordingly. The 
variable slope parameter uses any slope possible to fit the data. We were interested in 
exploring both possibilities and analyzing the data thoroughly to ensure the most accurate 
method was used, with that in mind we sought to increase the number of data points and vary 
the slope to create a well fit curve over more concentrations, increasing the accuracy of the 
interpretation.   Interestingly, the EC50 calculations were within 4 nM of each other.  
 
 
 
 
45 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7 Increased Number of Dilutions Increases Accuracy of EC50 Determination. Representative 
EC50 graph and corresponding effective concentration. Huh-7.5 cells were seeded at 1.5 x 105 cells/well 
in 6-well dishes. Cells were infected at an MOI of 0.1 and treated with 12 10-fold dilutions of RSRR-2. 
The treated infections were incubated for 4 days. On day 4 supernatant was clarified and subjected to 
RNA extraction and QRT-PCR. EC50 analyses were carried out with Graphpad Prism software. All points 
were quantified in triplicate. The red curve represents a fixed slope analysis and the blue curve 
represents a variable slope analysis. 
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Chapter 5 Discussion 
 
The field of hepatitis C treatment has recently been revolutionized by the discovery and 
development of several classes of highly effective antiviral compounds14. These drugs were 
discovered primarily through high-throughput screens using the replicon model in vitro. While 
this is excellent for discovery and early characterization of compound efficacy and viral 
resistance, this model does not reflect the complex interactions of non-structural proteins, host 
factors and structural proteins throughout the complete viral life cycle. With that in mind, 
mutations arising during in vitro characterization may indeed be artifacts of this caveat.  
While this may not seem important for early analyses of compound efficacy and mechanisms of 
action, the downstream application of these drugs, especially in combination may be hindered 
by an incomplete understanding of the viral response to drug pressures. For instance, a ‘drug 
resistant’ mutation in the replicon may have lethal effects in a fully infectious system due to the 
polyfunctional nature of the target protein. One paper demonstrating this phenomenon 
analyzed NS4A mutations, some of which caused little to no decrease in RNA replication but 
had severe impacts on assembly and release of viral particles112. A resistance mutation 
identified in the replicon may indeed be resistant in the context of replication, but when paired 
with the life cycle may severely inhibit downstream viral machinery. Considering the ever 
increasing need for optimization with novel compounds and combinations, a fully infectious 
viral assay may be the tool necessary to completely characterize viral resistance and 
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recommend novel treatment regimens. With this in mind, we set out to develop an assay to 
analyze compound efficacy in the context of a complete viral life cycle.  
To begin we chose several common protease inhibitor mutations to characterize, namely: 
L36M, T54A, R155K and I170A.  Interestingly, the three conservative amino acid substitutions 
showed less than a 1 log decrease in viral fitness as measured by a viral titration assay (Figure 
3.1). This seemed rather intuitive and the striking reduction of fitness when the Isoleucine at 
position 170 was mutated to an alanine reflected the non-conservative nature of this 
substitution and it’s relatively low frequency of observation clinically and in the literature. The 
panel of mutants selected were all viable and, with the exception of I170A, highly productive in 
the context of our genotype-2a construct. This reflected similar observations in genotype-1172.  
To further confirm our preceding data concerning the fitness of the mutants we decided to 
focus on the most clinically relevant of the four in a competition assay (Table 3.1). R155K was of 
significant interest during the period of these experiments and remains a fascinatingly fit 
mutant in the context of drug resistance. This mutation was of particular interest due to its high 
fitness in vitro and in vivo, its ability to persist in a quasispecies containing wild-type sequences 
and its potential for harbouring multiple resistance mutations (most likely due to its low impact 
on fitness)176,177.  In the competition assay, we observed that even in the context of a 
quasispecies harbouring 1 wild-type virus for every 10 R155K mutants, the R155K mutation 
maintained dominance over a 3 day culture. This confirmed our titration data and was further 
validated by the existing literature176,177.  
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Recently, a colleague from the laboratory developed an assay for analysis of genetic barrier 
(Morris, Taylor et al, manuscript in preparation). In the interest of a thorough analysis of fitness 
we subjected T54A and R155K to a similar long term culture period to evaluate the genetic 
pathway to a wild-type sequence. This assay assumes the less-fit mutant virus will always 
mutate towards the more-fit wild-type sequence when no drug pressure is applied. This 
assumption is rather intuitive considering the nature of the wild-type sequence to be more fit 
than the mutant and often competes to dominate the quasispecies. It has further been 
observed that in vivo the viral polymerase causes mutations through nucleotide transitions 
(pyrimidine to pyrimidine, purine to purine) more often than transversions (purine to 
pyrimidine or vice versa)196. We were interested to see how this would apply to highly fit 
antiviral resistance mutations, and sought to further understand the mechanisms of resistance 
mutation. Intriguingly, after culturing for 30 days or more, neither T54A nor R155K reverted to 
the wild-type sequence, providing further evidence that these mutants are highly fit in the 
context of our virus and can remain in the quasispecies for extended periods of time, similar to 
observations of maintenance in patient quasispecies176  
Finally, to complete the analysis of our panel of mutations we sought to develop an assay to 
assess the efficacy of compounds in the face of resistance mutations. To do this, we began by 
assessing viral growth in 6-well plates (Figure 4.2) and optimizing our collection of samples 
based on a 4-day peak in viral growth. We tested telaprevir at 10-fold logarithmic dilutions and 
analyzed the data using a three-parameter dose response curve. Our results in Figure 4.5 
indicated that the mutations introduced into our adapted virus were indeed bona fide 
resistance mutations in our system. Both T54A and R155K showed a 10-fold logarithmic 
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increase in the drug concentration necessary to inhibit virus propagation by 50%. Consistent 
with previously established EC50s with telaprevir, all of the viruses tested were in the 
nanomolar range172. This established our assay and confirmed the resistant phenotype of T54A 
and R155K in a genotype-2 adapted virus strain. Two caveats to our design at this stage were 
the minimal number of data points for curve-fitting and the requirement for viruses with titers 
of 15000 ffu/ml or more to accommodate an MOI of 0.1. A common criticism of our work 
among experts is the genotype-2 nature of our viral strain. Considering the primary target of 
protease-inhibitor therapy is HCV genotype-1 infected patients, it is a common misconception 
that these drugs have little to no effect on genotype-2, or that due to the high efficacy of the 
classical SOC in achieving SVRs in genotype-2 there is no need to research the topic further. In 
stark contrast to these points, it has still been suggested that the original PIs improve the 
efficacy of SOC and can be used for hard to treat genotype-2 patients197–201. Even beyond the 
scope of specifically testing for genotype 2, our assay has been shown effective to analyze 
mutations, and confirm their resistant phenotype. Future studies in our laboratory could 
include passaging the virus in the presence of drug and confirming resistance in the EC50 assay. 
Regardless of genotype the mechanism of viral mutation during replication remains the same. 
Our system still provides a legitimate map of interactions and plausibly more accurately defines 
the resistance profile due to the intact downstream interactions of NS proteins.   
Once the assay had been developed and implemented with resistant mutations we moved on 
to analyze a collaborators compounds using the same protocol.  Compounds representing two 
distinct classes of antivirals, NS5B and NS5A inhibitors, were tested at 10-fold logarithmic 
dilutions with our wild-type strain of virus (Figure 4.6. Consistent with the observed EC50s in the 
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literature14, NS5B inhibitors showed nanomolar EC50s while the NS5A inhibitors required 
picomolar amounts to inhibit viral growth by 50%. This further validated our system and was 
the first assessment of these novel compounds in a fully infectious system.  
To finalize our analysis we chose an NS5B inhibitor (RSRR-2) to use in an optimized protocol, 
increasing data points and providing the basis for more accurate EC50 determination (Figure 4.7. 
We increased the number of data points from 7 to 12 and used both three-parameter and four-
parameter dose-response calculations to evaluate the compounds efficacy. Interestingly, we 
saw that both analyses results in similar EC50s. That being said, the increase in data points still 
provided a more accurate assessment of the necessary concentration to inhibit viral 
production. To increase the assays utility, it would still have to be scaled up to increase its 
throughput and optimized with lower requirements of virus for both resistance and compound 
analysis. 
We present here, for the first time, the analysis of drug resistant mutations in our adapted viral 
strain, the development of an assay for compound analysis and the results of analyses with 
novel compounds from multiple antiviral drug classes. Several groups have provided similar 
insights, with similar systems192–195, but we strongly believe that our system has the most 
potential for accurate and high throughput analysis of compounds and resistance mutations 
due to the wide dynamic range of our naturally fit wild-type strain, the ease of manipulation 
following treatment and the commercial nature of our QRT-PCR analyses. Potential future 
studies could include the identification of key residues involved in compound mechanisms of 
action. By selecting and substituting key residues in NS proteins, and analyzing the resultant 
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EC50s we could further probe the mechanisms of actions and improve the efficacy of novel 
compounds. Due to the availability of this assay in our lab, Dr. Russell has recently received 
funding from Merck Sharpe & Dohme Corp to evaluate a number of compounds they have in 
development and for which they do not currently know the mechanism of action. The assay is 
also being used in our lab to evaluate potential antiviral efficacy of 70 nucleoside analog-like 
compounds received from Dr. Paris Georghiou in the Department of Chemistry here at 
Memorial. We have also created the potential to optimize treatment regimens by passaging the 
virus in the presence of multiple drugs, individually or in combination. Following passage we 
could analyze the sequences, clone them into our construct and assess antiviral efficacy against 
the mutants. This process would increase the stringency of resistance analysis and provide 
insights into viable resistance mutations arising from combination therapy. This type of in vitro 
analysis remains to be done and would provide important information in therapeutic design. 
We have developed a tool for compound analysis that has a wide range of applications in the 
field of HCV compound development that could easily be adapted to facilitate evaluation of 
putative antiviral agents targeting other viruses in similar systems.  
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Figure A1. miRNA Mimics Downregulate Infectious Virus Production. miRNA mimics were transfected 
into Huh-7.5 cells and infected with JFH1T at an MOI of 0.1 24 hours post-transfection. 48 hours post-
infection supernatants were collected, filtered and subjected to an FFU assay, as described in Chapter 2.  
